Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 3/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | BRD1 | O95696 | 1/20 | 0.31 |
| ▸ | TAF1 | P21675 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25378173 | 0.79 | CDK4 (0.35) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL13836115 | 0.76 | PSMD14 (0.37) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL436336 | 0.76 | MEN1 (0.41) | SLC6A2SLC6A4CMA1ALDH1A1PTPN11 | |
| SCHEMBL30109166 | 0.76 | MEN1 (0.41) | SLC6A2SLC6A4CMA1ALDH1A1PTPN11 | |
| SCHEMBL2625811 | 0.74 | CDK4 (0.41) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL30847966 | 0.74 | PRKCI (0.39) | CMA1PRKCIALDH1A1PTPN11 | |
| SCHEMBL2052186 | 0.74 | CYP1A2 (0.38) | CDK2CMA1ALDH1A1 | |
| SCHEMBL6505950 | 0.74 | SLC6A2 (0.35) | SLC6A2SLC6A4BACE1NOS1CA12 | |
| SCHEMBL29989147 | 0.74 | CDK4 (0.41) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL4387353 | 0.74 | PRKCI (0.39) | CMA1PRKCIALDH1A1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409615-A | 2- (Indol-3-yl) phenol compound and synthesis method thereof | 湘潭大学 | 2025-02-11 | — | — | CN | claimed |
| CN-116813639-A | Synthesis method of polysubstituted [1,2,3,4,5] pentathio [6,7-b ] indole and derivative | 衡阳师范学院 | 2023-09-29 | — | — | CN | claimed |
| CN-113564623-A | Method for preparing isatin compound by electrochemically oxidizing N-substituted indole derivative | 福建师范大学 | 2021-10-29 | — | — | CN | claimed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739671-A1 | NEW COMPOUNDS | Aston University (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250197411-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | disclosed |
| CN-1350520-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-05-22 | — | — | CN | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1140814-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000039081-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | IL1B, IL1A, NFKBIA | CDK4 1698/4885CCND1 2054/4885CCNE2 1624/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CDK4 554/4885CCND1 190/4885CCNE2 1003/4885 |
| US-20250197411-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | CDK4 107/4885CCND1 3413/4885CCNE2 4041/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | CDK4 544/4885CCND1 569/4885CCNE2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.